Latest Investment Funds biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

Call now open for healthtech projects for CRAASH Barcelona 2021

by Biocat

3 years ago
healthtech, CRAASH Barcelona

If you have an emerging, cutting-edge technology project based on (or with a link) to the BioRegion of Catalonia and want to launch it to market, submit your proposal by June 15 and train with experts...

Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

3 years ago
Mirum Pharmaceuticals, Vivet Therapeutics, Columbus Venture Partners, Ysios Capital

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Viv...

BIOLAN y CIC bioGUNE desarrollarán conjuntamente un test ELISA para la detección de anticuerpos frente a SARS-CoV-2 y sus variantes

by CIC bioGUNE

3 years ago
CIC bioGUNE, BIOLAN, ELISA, inmunoensayos

Esta actuación de colaboración se enmarca en un acuerdo más amplio alcanzado entre CIC bioGUNE y BIOLAN en áreas encaminadas al diagnóstico de enfermedades y otras aplicaciones para la salud.

Synendos Therapeutics Expands Series A to CHF 24 million with new investment. Ysios Capital joins other investors

by Ysios Capital

3 years ago
Ysios Capital, Eurostars Funding Programme, SERIs, Synendos Therapeutics, Central Nervous System

Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today annou...

Adcendo raises EUR 51 Million in Series A Financing led by Novo Holdings and Ysios Capital to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

by Ysios Capital

3 years ago
Adcendo, Gilde Healthcare, Ysios Capital, RA Capital Management, Novo Seeds

Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...

Flomics ha sido seleccionada para el programa EIT Health Bridgehead

by Flomics Biotech SL

3 years ago
Bridgehead Global, Bridgehead Europe, FlomicsBiotech

El programa destinado a proyectos del sector de la salud ha seleccionado a 3 startups españolas para Bridgehead Global y a 6 para Bridgehead Europe

Un estudio que utiliza la Inteligencia Artificial para el diagnóstico del melanoma, ganador del Premio PRBB al mejor trabajo de investigación de bachillerato

by UPF - Universitat Pompeu Fabra

3 years ago
Inteligencia Artificial, melanoma, diágnostico, diagnóstico

La ganadora del XVI Premi PRBB que reconoce al mejor trabajo de investigación en Ciencias de la Salud y de la Vida es Núria González Cuesta, alumna de segundo de Bachillerato en el Instituto France...

Tratamientos más específicos y medicina personalizada gracias a los nuevos organ-on-chip

by CIBER-BBN

3 years ago
organ-on-chip, tecnología, sistemas microfluídicos in vitro

Dos trabajos de investigadores del CIBER-BBN en el Instituto de Microelectrónica de Barcelona del CSIC hacen una revisión de los últimos avances de la tecnología organ-on-chip en la simulación...

Cytoki Pharma raises $45 million Series A financing

by Ysios Capital

3 years ago
Ysios Capital, +ND Capital, Seventure Partners, Lundbeckfonden Emerge, Cytoki Pharma

Cytoki Pharma ApS, a private biotech company incorporated in Copenhagen, Denmark, today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together ...

Neuroelectrics Raises $17.5M to Advance Clinical Trials for the Treatment of Epilepsy and Major Depressive Disorder with a New Platform for Treating Brain Dysfunction

by Neuroelectrics

3 years ago
Morningside Ventures, Neuroelectrics

Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures. The funds will be used to further develop Neuroelec...

The Gregorio Marañón Hospital creates a spin-off to market the drug that protects the kidney

by GENESIS Biomed

3 years ago
Cilastatin project, kidney, Telara Pharma, GENESIS Biomed

The Cilastatin project arose thanks to the research carried out by the deceased Dr. Alberto Tejedor, who was Nephrology Service section chief at the Gregorio Marañón General University Hospital and ...

VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

by Vall d’Hebron

3 years ago
ABTL0812, Ability Pharmaceuticals, clinical trial, pancreatic cancer

The biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...